The U.S. Army is seeking preproposals for the CADENCC prototype project, an enabling capability to accelerate clinical trial startup for chemical, biological, radiological, and nuclear (CBRN) defense. The effort will focus on Phase I/II clinical trials for pre-exposure prophylaxis, post-exposure prophylaxis, and early treatment products, potentially under the Animal Rule. It will use Master Protocols, technologies supporting decentralized trial operations, and a pre-positioned clinical trial site network. Awards would be made under Other Transaction Authority, with possible follow-on production agreements. Prospective offerors should note that evaluation will consider technical merit, military relevance, funding availability, technology readiness level, key personnel, facilities, regulatory compliance, and past performance.

The U.S. Army seeks proposals to develop CADENCC, an enabling capability to accelerate clinical trial startup for CBRN defense through Master Protocols, decentralized trial technologies, and a pre-positioned clinical trial site network. The work will primarily support Phase I/II trials for pre- and post-exposure prophylaxis and early treatment products, potentially under the Animal Rule, with awards made under Other Transaction Authority for prototype projects. This is a formal request for preproposals; the government will evaluate submissions and may request full proposals, with award depending on funds availability and alignment with program priorities. Offerors must be registered in SAM.gov, and submissions will be assessed on technical merit, military relevance, TRL (must be 4 or above), key personnel, facilities, cost reasonableness, best value, and past performance. A successful prototype effort may lead to a follow-on production contract or transaction.